Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years-Reference-Cited by-同舟云学术

Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years

Published:2020-09-28 Issue:24 Volume:26 Page:6475-6482
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Bazarbachi Ali,Schmid Christoph,Labopin Myriam,Beelen Dietrich,Wolfgang Blau Igor,Potter Victoria,Niittyvuopio Riitta,Socié Gerard,Blaise Didier,Sanz Jaime^ORCID,Ciceri Fabio,Abou Dalle Iman,Spyridonidis Alexandros^ORCID,Bug Gesine,Esteve Jordi,Savani Bipin N.^ORCID,Nagler Arnon,Mohty Mohamad

Funder

no fuding

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT;Bone Marrow Transplantation;2024-08-20

2. Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study;Leukemia & Lymphoma;2024-08-11

3. Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation;Blood;2024-07-18

4. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients;Blood Cancer Journal;2024-05-02

5. Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience;Frontiers in Oncology;2024-04-12